Royal Bank of Canada Sells 28,303 Shares of Transcat, Inc. $TRNS

Royal Bank of Canada trimmed its position in Transcat, Inc. (NASDAQ:TRNS) by 17.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 132,447 shares of the scientific and technical instruments company’s stock after selling 28,303 shares during the period. Royal Bank of Canada’s holdings in Transcat were worth $9,728,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in TRNS. Lazard Asset Management LLC purchased a new stake in Transcat in the second quarter worth about $54,000. Tower Research Capital LLC TRC grew its stake in shares of Transcat by 245.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,123 shares of the scientific and technical instruments company’s stock worth $97,000 after buying an additional 798 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Transcat in the 4th quarter worth approximately $236,000. Balyasny Asset Management L.P. bought a new position in Transcat during the 4th quarter valued at approximately $247,000. Finally, Price T Rowe Associates Inc. MD increased its position in Transcat by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,265 shares of the scientific and technical instruments company’s stock valued at $299,000 after buying an additional 432 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Key Stories Impacting Transcat

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat’s latest quarterly results exceeded expectations, with earnings of $0.51 per share versus the $0.38 consensus estimate and revenue of $92.95 million compared with expectations of $86.55 million. This indicates solid operating momentum, although the results are not the primary focus of today’s trading. TRNS Q2 deep dive: Service segment drives growth, margin pressures persist
• Neutral Sentiment: Northland’s $95 price target and “Market Perform” rating indicate a neutral stance rather than a bullish or bearish recommendation. Transcat Rating Lowered to Market Perform at Northland Securities
• Negative Sentiment: Northland cut its Q3 2027 EPS forecast to $0.20 from $0.38 and lowered FY2027 EPS to $1.71 from $1.86. It also reduced estimates for FY2028 to $2.12 from $2.33, FY2029 to $2.58 from $3.18, and FY2030 to $3.01 from $3.51.
• Negative Sentiment: The firm additionally lowered Q2 2027 EPS to $0.41 from $0.45, Q4 2027 EPS to $0.60 from $0.62, and FY2031 EPS to $3.53 from $3.88. The broad-based reductions imply weaker-than-previously-expected earnings growth and are likely weighing on the stock.
• Negative Sentiment: Transcat trades at a very elevated valuation, with a trailing P/E above 250. Downward revisions therefore create greater downside sensitivity, particularly while the stock is near its 52-week high.

Transcat Price Performance

NASDAQ TRNS opened at $93.11 on Monday. Transcat, Inc. has a one year low of $50.23 and a one year high of $96.60. The stock has a 50-day moving average of $89.60 and a 200 day moving average of $79.73. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.11 and a current ratio of 2.49. The company has a market capitalization of $871.51 million, a price-to-earnings ratio of 251.65 and a beta of 0.68.

Transcat (NASDAQ:TRNS) last posted its earnings results on Tuesday, August 4th. The scientific and technical instruments company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.13. Transcat had a return on equity of 5.56% and a net margin of 0.99%.The company had revenue of $92.95 million for the quarter, compared to the consensus estimate of $86.55 million. On average, sell-side analysts forecast that Transcat, Inc. will post 1.74 EPS for the current year.

Analysts Set New Price Targets

TRNS has been the topic of several analyst reports. Weiss Ratings raised Transcat from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 28th. Northland Securities downgraded Transcat from an “outperform” rating to a “market perform” rating and set a $95.00 price target for the company. in a report on Wednesday, August 5th. Wall Street Zen raised Transcat from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Finally, Zacks Research upgraded shares of Transcat from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $105.50.

Transcat Profile

Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.

In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.